NCT07271446 2025-12-09
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Precision Biotech Taiwan Corp.
Phase 1 Completed
Clinical Trials
21 trialsNCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT02191891 2025-06-25
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 1 Completed
NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT01214616 2025-02-07
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02171650 2025-01-23
BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT04448379 2020-12-28
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1 Unknown
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT01206816 2019-02-01
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02020577 2017-06-22
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01090011 2015-10-02
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02171663 2015-01-28
Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171637 2014-06-24
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171676 2014-06-24
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171702 2014-06-24
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02171728 2014-06-24
Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02171741 2014-06-24
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT01169675 2014-06-09
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00730821 2009-08-21
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed